Navigation Links
Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
Date:9/24/2009

FRAZER, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year. The FDA decision on approval of NUVIGIL as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel is expected by December 29, 2009. There currently is no FDA-approved treatment for jet lag disorder.

The NUVIGIL sNDA is based on data from a Phase III pivotal study that evaluated the efficacy and safety of NUVIGIL (50 or 150 mg/day) in 427 healthy adults over three days during travel from the United States to Europe. These data were presented earlier this year at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies.

About NUVIGIL

NUVIGIL, the longer-lasting isomer of modafinil, was launched in the United States in June 2009 and is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not approved as a treatment for jet lag disorder or its associated symptoms. The NUVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson syndrome, that has been reported in adults and children taking modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (five pe
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... , April 26 e-MDs, an industry leader ... and practice management (PM) solutions, announced they have been selected ... Alaska EHR Alliance (AEHRA).   e-MDs was identified through ... Alaska healthcare providers looking to incorporate an EHR in ...
... 26 Sirion Therapeutics, Inc., a privately held ophthalmic ... is now commercially available.  Zirgan™, which was approved by the ... is a topical ophthalmic antiviral indicated for the treatment of ... , , ...
Cached Medicine Technology:Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 2Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 3Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 4Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/10/2014)... as tempting as full-fat equivalents could be heading ... how proteins can replace fats without affecting foodstuffs, ... Engineering and Physical Sciences Research Council (EPSRC), a ... Edinburgh has produced modified proteins that easily break ... behaviour of fats during food manufacture. The proteins ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2
... triples risk of disease, study funds , , WEDNESDAY, ... to be predictors of esophageal cancer have been identified ... M. D. Anderson Cancer Center team pinpointed 11 single-nucleotide ... with esophageal cancer. , Each of these unfavorable genotypes ...
... Marketing Messages for Advair,and Xolair, According to a ... Nov. 5 Decision Resources one of the,world,s ... and,healthcare issues, finds that physicians and patients respond ... to use.,Physicians indicate that brands conveying messages of ...
... Stay Balanced Through the ... ... and New York Times best-selling author Ellie Krieger, of Food Network,fame, ... health. Yo-Plus contains live and active probiotic cultures,specifically designed for digestive ...
... PITTSBURGH, Nov. 5 CardiacAssist, Inc. announced that,it reached a ... System,performing at least one TandemHeart case during the third quarter ... highest year on,year growth in case activity with a leap ... 70 % and 497 %. Through nine months of 2008,CardiacAssist ...
... for passengers taking 7- to ... 9-hour flights, ... Minerva Cardioangiologica reveals Pycnogenol(R), pine bark,extract from the French maritime pine tree, ... a brain CT scan and a,scoring system, showed Pycnogenol(R) lowered symptoms of ...
... companies is often dependent on their ability to do deals ... A Comprehensive Assessment of Valuation in the Pharmaceutical Sector, the ... aspects of deal-making, including valuations and royalty rate calculations. ... ...
Cached Medicine News:Health News:Researchers ID Genetic Markers for Esophageal Cancer 2Health News:Physicians Rank Schering-Plough's Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 2Health News:Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health 3Health News:CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results 2Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:Determining Valuations in Challenging Times 2Health News:Determining Valuations in Challenging Times 3Health News:Determining Valuations in Challenging Times 4
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Medicine Products: